June 29, 2020 10:05 AM EDTUpdated 10:32 AM
FDA+

Heron earns a sec­ond slap­down from the FDA on pain med — shares with­er

John Carroll

Editor & Founder

In­ter­cept wasn’t the on­ly biotech in line for a drub­bing to­day. In ad­di­tion to the re­jec­tion for NASH, Heron Ther­a­peu­tics $HRTX put out word …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Stem cell start­up spun out of George Church’s lab rais­es $75M

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times